| NCT ID | NCT06301438 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Advanced Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 103 participants |
| Start Date | 2024-05-03 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 103 participants in total. It began in 2024-05-03 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed advanced breast cancer * Hormone receptor-positive and human epidermal growth factor receptor 2-negative * ECOG 0-1 Exclusion Criteria: * Pregnant or breastfeeding * History of immunodeficiency
Contact & Investigator
Wenjin Yin
PRINCIPAL INVESTIGATOR
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Frequently Asked Questions
Who can join the NCT06301438 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06301438 currently recruiting?
Yes, NCT06301438 is actively recruiting participants. Contact the research team at yinwenjin@renji.com for enrollment information.
Where is the NCT06301438 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06301438 clinical trial?
NCT06301438 is sponsored by RenJi Hospital. The principal investigator is Wenjin Yin at Renji Hospital, School of Medicine, Shanghai Jiaotong University. The trial plans to enroll 103 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.